07 June 2022
: Case report 
Thrombotic Microangiopathy Secondary to Systemic Sclerosis with Severe Complement Activation Not Responsive to Eculizumab: A Case Report
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Unexpected drug reaction
Masahiko Nakamura1ABCDEF*, Tomohiro Abe
1ABCDE, Hidenobu Ochiai1ACDE
DOI: 10.12659/AJCR.936116
Am J Case Rep 2022; 23:e936116
Table 1. Laboratory values at admission.
| Normal range | ||
|---|---|---|
| White blood cell (×10/L) | 7.9 | 4.5–11.0 |
| Hemoglobin (g/L) | 54 | 116–148 |
| Schistocyte(%) | <1.5% | Negative |
| Platelet count (×10/L) | 7 | 150–450 |
| Activated partial thromboplastin time (sec) | 48 | 25–40 |
| Prothrombin time-international normalized ratio | 1.86 | 0.90–1.10 |
| Fibrin degradation products(mg/L) | 14.5 | <5.0 |
| D-dimer(nmol/L) | 42.2 | <2.74 |
| Blood urea nitrogen (mmol/L) | 53.3 | 2.9–8.2 |
| Creatinine (µmol/L) | 543 | 53–106 |
| Total bilirubin (µmol/L) | 11.9 | 2–18 |
| Aspartate aminotransferase (µkat/L) | 0.82 | 0.34–0.82 |
| Alanine aminotransferase (µkat/L) | 0.63 | <0.67 |
| Lactate dehydrogenase (µkat/L) | 3.93 | 1.72–3.38 |
| Creatinine kinase (µkat/L) | 3.28 | 0.85–3.40 |
| C-reactive protein (nmol/L) | 2057 | <13.3 |
| Procalcitonin (µg/L) | 12.2 | <0.5 |